Frankfurt - Delayed Quote EUR

Danaher Corporation (DAP.F)

Compare
229.40
-1.15
(-0.50%)
As of 8:01:04 AM GMT+1. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Steven M. Rales Co-Founder & Chairman -- -- 1951
Mr. Rainer M. Blair President, CEO & Director 5.19M -- 1964
Mr. Mitchell P. Rales Co-Founder & Director -- -- 1957
Mr. Matthew R. McGrew CFO & Executive VP 2.5M -- 1972
Dr. Jose-Carlos Gutierrez-Ramos Ph.D. Senior VP & Chief Science Officer 2.04M -- 1962
Ms. Georgeann F. Couchara Senior Vice President of Human Resources 1.62M -- 1977
Mr. Christopher M. Bouda VP & Chief Accounting Officer -- -- --
Mr. John Bedford Vice President of Investor Relations -- -- --
Mr. Brian W. Ellis J.D. Senior VP, General Counsel & Chief Compliance Officer 1.89M -- 1967
Mr. Daniel A. Raskas J.D. Senior Vice President of Corporate Development -- -- 1967

Danaher Corporation

2200 Pennsylvania Avenue, North West
Suite 800 West
Washington, DC 20037-1701
United States
202 828 0850 https://www.danaher.com
Sector: 
Healthcare
Full Time Employees: 
61,000

Description

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.

Corporate Governance

Danaher Corporation’s ISS Governance QualityScore as of January 1, 2025 is 7. The pillar scores are Audit: 8; Board: 10; Shareholder Rights: 2; Compensation: 2.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

January 29, 2025 at 1:30 PM UTC

Danaher Corporation Earnings Date

Recent Events

December 27, 2024 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers